Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. - Wikidata - wikimedia - TriplyDB

Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.

Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.

http://www.wikidata.org/entity/Q34269134

about

RNA vaccines in cancer treatment Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis.Morphological observation of tumor infiltrating immunocytes in human rectal cancer A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival.Optimizing dendritic cell-based approaches for cancer immunotherapy Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo Vaccines: all things considered.Intralymphatic immunotherapy and vaccination in mice.A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer.Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.Trial watch: Dendritic cell-based interventions for cancer therapy Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes.Vaccine-based approaches to squamous cell carcinoma of the head and neck.New routes for allergen immunotherapy.A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.Taming cancer by inducing immunity via dendritic cells.A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity.Reengineering dendritic cell-based anti-cancer vaccines.Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.Progress and challenges in the vaccine-based treatment of head and neck cancers.Dendritic cell-based cancer vaccination: quo vadis?Biology of human cutaneous melanoma Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression.Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.Dendritic cell-based vaccines for the therapy of experimental tumors.Therapeutic vaccines in renal cell carcinoma.Immunotherapy for the treatment of glioblastoma.Various ways to improve whole cancer cell vaccines.Dendritic cell vaccine against leukemia: advances and perspectives.Cellular immunotherapy of cancer: an overview and future directions.Developing immunotherapeutic strategies to target brain tumors.

P2860

Q21296852-79E79ED5-F58A-4BC5-8443-F401FFA8B611 Q26830857-C06161EB-573C-424D-8D80-5FDE0B49C624 Q27686800-E71D0E7D-2071-43D0-92CB-48AF46F34BB9 Q30434822-FCD16050-FA67-483B-B579-903F17E0B014 Q33238645-C08D5D7C-AB82-4F6D-A27F-8B7AE7551FB1 Q33724878-AC64CD2A-3801-4508-A880-A97FA565AD36 Q33731220-2854194F-336F-4C55-9BD5-D137DAED533E Q33840446-6E239065-FB22-4521-9BEB-51AE34ACAB63 Q34365990-A14913A7-515B-437C-B98F-822D565841A2 Q34637535-127CE148-DD46-4BB3-9588-4DAD4619F904 Q34666875-AD365FD1-A59E-402B-9B2B-77092105D778 Q34975057-73F70597-826D-4886-BC21-840CB946CBA9 Q35389863-9B789F4B-FC0F-49D0-A098-EEFCE3545512 Q35621559-2518030A-6B5B-4A40-A9FC-B6727786059C Q35807188-679F286C-15A5-470F-BD80-8897952672DD Q35899068-8B1CB750-642C-453E-97BC-96F04660E663 Q36388529-F479FF6A-893D-40D6-A597-2350FAD410BE Q36478070-F3CFFD56-893E-4B4C-8EB3-58B058840B1C Q36610161-E2A48937-5A28-4D9D-B819-3D5EC0DAA66F Q36714541-8F698881-EEE5-4FA3-84D2-D8F7C9D3EDF9 Q36864957-049E2AD7-4F70-43A4-BD9F-D428016EC7FE Q36958112-D6F00436-13E8-49A2-A6A8-D10363909562 Q36990604-E926CB57-1DA7-4A15-B409-8B79783C0410 Q37002959-F04144F2-CE18-4366-85FE-4C796FFF52C8 Q37052943-D2FF4198-9C38-4588-85D9-13C709757725 Q37118177-9CF5D0DB-3605-4422-BC53-E23FCF3C6EC3 Q37154132-27C31D04-8ACD-4EBB-A071-9EA27C3F3AB8 Q37178648-79319C42-7C72-4D6F-AF7F-161870701EB9 Q37224926-36064841-0219-42C1-8FC3-6C462530D263 Q37259624-10A5C3B9-C2C7-407E-B0ED-E90B19FC706D Q37307195-E35507F7-DD6C-42F6-BC3F-E499DCB64064 Q37428061-33C99348-0D13-4C94-BDD6-7F9D1B3B6A4C Q37773237-4B2E51CD-5568-43AB-8132-9A7034750626 Q37773259-6C9C0ED8-8F4C-4714-BA2F-7507C38BF981 Q37922585-63AE3D10-6222-45B9-B13D-E67E9691D3A5 Q37980026-55794315-093D-4E8A-A280-03D1E282B685 Q38206582-D8D0CA44-E6B4-4753-AC66-F769910975EC Q38210813-E5D46D37-4692-450A-B815-0EC21F4DA41C Q38673161-5FEC5F53-CA3D-4EA0-B449-DCA72189A58F Q38851464-B9D21E8E-4370-4717-8E7C-FC47A80DE549

P2860

Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.

http://www.wikidata.org/entity/Q34269134

description

2003 nî lūn-bûn

@nan

2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Intranodal administration of p ...... function in melanoma patients.

@ast

Intranodal administration of p ...... function in melanoma patients.

@en

Intranodal administration of p ...... function in melanoma patients.

@nl

type

label

Intranodal administration of p ...... function in melanoma patients.

@ast

Intranodal administration of p ...... function in melanoma patients.

@en

Intranodal administration of p ...... function in melanoma patients.

@nl

prefLabel

Intranodal administration of p ...... function in melanoma patients.

@ast

Intranodal administration of p ...... function in melanoma patients.

@en

Intranodal administration of p ...... function in melanoma patients.

@nl

P1433

Q34269134-1A06C6D1-EDFF-47CF-A6F3-CB0388B87BCC

P1476

Q34269134-81F73A34-82F6-429D-8129-8BE5CAAC10AA

P2093

Q34269134-0EEF0CA4-63E7-4C80-8B6A-76DC4FC532FE

Q34269134-2040BA42-67FE-410B-B884-BC5F5D27A43C

Q34269134-4A881C76-028E-4560-A434-1DF6D5604A0C

Q34269134-85867D02-FAC0-4054-978B-3AD901122239

Q34269134-9D431F8F-E0DC-4507-A85E-077A299B0C91

Q34269134-B976843F-EF2D-408C-B1AD-188B4B0F57B7

Q34269134-DFAA5BEA-1756-4F89-B2FD-0D32C86958CE

Q34269134-E512BF1B-605D-472A-94AE-ACC1AE20B88D

Q34269134-E7237ED0-2C99-470C-B391-F3A0C6714CD9

P304

Q34269134-BF1C2348-977B-4F5A-81E9-5727215E387F

P31

Q34269134-F455A80A-8D7E-41A8-98FD-C0C17768D5C0

P356

Q34269134-1C821887-DF96-4C70-9880-719DF4646418

P407

Q34269134-D52A6B20-9857-417D-921E-59E5E7B35BF0

P433

Q34269134-E1E8B2FE-2EED-4229-A1A5-4DC40A937F4B

P478

Q34269134-113C8D07-353C-4B97-802E-FFDB45BC23CF

P577

Q34269134-DFC9A555-35D8-4B8A-A47B-E60919F617EA

P698

Q34269134-B008916C-539F-460D-86D8-13BE8AF99993

P921

Q34269134-729C45EC-5BC8-4737-A312-E8BD13973390

P356

JCO.2003.04.042

P1433

Journal of Clinical Oncology

P1476

Intranodal administration of p ...... function in melanoma patients.

@en

P2093

Brian J Czerniecki

http://www.w3.org/2001/XMLSchema#string

Gary Koski

http://www.w3.org/2001/XMLSchema#string

Harvey Nisenbaum

http://www.w3.org/2001/XMLSchema#string

Isabelle Bedrosian

http://www.w3.org/2001/XMLSchema#string

Mark Faries

http://www.w3.org/2001/XMLSchema#string

Paul Zhang

http://www.w3.org/2001/XMLSchema#string

Peter A Cohen

http://www.w3.org/2001/XMLSchema#string

Rosemarie Mick

http://www.w3.org/2001/XMLSchema#string

Shuwen Xu

http://www.w3.org/2001/XMLSchema#string

P304

3826-3835

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.04.042

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2003-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14551301

http://www.w3.org/2001/XMLSchema#string

P921